Hologic, Inc. (HOLX)

FairStock Score: 51/100 — MIXED

Key Financials

Strengths

• Strong free cash flow generation of $848.6M with healthy 17.09% net margin
• Market leadership in women's health diagnostics and breast imaging with competitive moats
• Low leverage at 0.48 D/E ratio provides financial flexibility
• Recession-resistant business model through essential diagnostic products
• Low beta of 0.73 suggests stability relative to market volatility

Concerns

• Valuation is egregiously expensive at 31.29 P/E with negative 267% margin of safety vs Graham Number
• Return on capital metrics are weak: 10.86% ROE and 7.43% ROCE fail to justify premium pricing
• EV/EBITDA of 52.70x is unsustainable and signals investor euphoria
• Piotroski F-Score of 6/9 indicates deteriorating financial fundamentals and quality warnings

AI Analysis

Hologic presents a classic case of a quality business trading at an unreasonable price. Let me be direct: at $75.59, this company fails the margin of safety test dramatically. The Graham Number of $20.57 versus current price represents a negative 267% margin of safety—a red flag I cannot ignore. Yet the business itself deserves respect. With $1B quarterly revenue and 17% net margins, Hologic demonstrates pricing power in essential diagnostics and women's health imaging. The free cash flow generation of $848.6M annually is respectable, though the 1.1% FCF yield reveals the valuation excess. The company operates in attractive markets—molecular diagnostics and breast imaging benefit from secular tailwinds and recurring revenue patterns. However, the 31.29 P/E ratio paired with modest ROE of 10.86% and concerning ROCE of 7.43% tells me shareholders aren't being rewarded appropriately for capital deployed. The EV/EBITDA of 52.70x is astronomical. The Piotroski F-Score of 6/9 suggests underlying financial quality issues, while the Altman Z-Score of 3.70 indicates adequate solvency but not exceptional strength. The modest 0.48 debt-to-equity is prudent, yet insufficient to justify current valuations. Hologic is a good business at a bad price. I'd wait for a market correction—ideally trading closer to $35-40 range—before reconsidering. Patience is the virtue value investors must cultivate, and this situation demands it.

Bull Case

Hologic benefits from durable secular trends in women's health screening and molecular diagnostics, with market consolidation supporting pricing power. Strong FCF generation and recurring revenue from installed diagnostic bases could justify gradual multiple expansion in a low-rate environment.

Bear Case

Multiple compression is inevitable as valuations normalize; even modest earnings disappointment would trigger significant downside given the 52x EV/EBITDA. Weak ROCE suggests capital is not being deployed efficiently, raising questions about long-term value creation.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer